欢迎访问《现代生物医学进展》编辑部！

目的：观察老年冠心病伴高脂血症患者应用瑞舒伐他汀治疗后的血脂及高敏C反应蛋白变化。方法：随机将2012 年7 月～ 2013 年6 月在本院治疗的68 例冠心病合并高脂血症患者分为两组，对照组采用常规治疗方法治疗，在对照组的基础上，治疗组给予瑞舒伐他汀，治疗周期均为2 个月，观察两组治疗前后的血脂及高敏C 反应蛋白水平的变化，并统计治疗期间两组不良反应发生情况。结果：两组治疗前的TC、TG、LDL-C、HDL-C 差异不显著，P＞0.05；而治疗后，两组的TC、TG、LDL-C水平均出现下降， HDL-C 水平上升趋势，但观察组治疗后的TC、TG、LDL-C 水平均明显低于对照组的（P＜0.05），观察组治疗后的HDL-C 水平均明显高于对照组的（P＜0.05）。治疗组治疗前的hs-CRP 为（3.86± 1.12）mg/L，对照组治疗前的hs-CRP 为（3.82± 0.84）mg/L，两组差异不显著（P＞0.05），治疗后，两组的hs-CRP 均出现下降，治疗组的hs-CRP 为（2.57± 0.66）mg/L，对照组的hs-CRP 为（3.23± 0.66）mg/L，两组差异显著（P＜0.05）。两组治疗后均出现轻微的不良反应症状，治疗组不良反应发生率为8.82%，对照组不良反应发生率为23.53%，两组差异不显著（x2=0.497，P=0.780＞0.05）。结论：瑞舒伐他汀能有效地改善冠心病合并高脂血症的血脂，降低高敏C 反应蛋白，值得在冠心病合并高脂血症临床治疗中更广泛地应用。

英文摘要:

Objective:To discuss the effects of rosuvastatin on hyperlipidemia blood lipids and high-sensitivityC - reactive protein of elderly patients with coronary heart disease.Methods:68 patients with coronary heart disease and hyperlipidemia treated in my hospital fromJuly 2012 to June 2013 were randomly divided into two groups, the control group (34 cases) was gave conventional treatment, on the basic of the control group, the observation group was gave rosuvastatin, with treattment period for 2 months. The level change of blood lipid and high-sensitivity C - reactive protein before and after treatment in the two groups were observed, and adverse reactions of two groups were Statistics during treatment.Results:The differences of TC, TG, LDL- C, HDL - C before treatment between the two groups was not significant, P>0.05, and after treatment, TC, TG, LDL - C levels of two groups fallen, and HDL - C level raise, but TC, TG, LDL - Clevel after treatment in the observation group were significantly lower than that in the control group (P<0.05), the level ofHDL-Cafter treatment in the observation group were significantly higher than that in control group (P<0.05). hs-CRP of treatment group before treatment was (3.86± 1.12) mg/L, and hs-CRP of control group for (3.82 ± 0.84)mg/L, there was no significant differences between the two groups (P > 0.05), hs-CRP of treatment group after treatment was (2.57± 0.66) mg/L, hs-CRP of control group for (3.23± 0.66) mg/L, therewas significant differences between the two groups (P>0.05).After treatment, patients in two groups appearedmild adverse symptoms, the incidence of adverse reactions in the treatment group was 8.82%, and the control group for 23.53%, with no significant differences between the two groups (x2= 0.497, P = 0.780 > 0.05).Conclusion:Rosuvastatin can effectively improve blood fat of coronary heart disease combined hyperlipidemia, and reduce high-sensitivity c-reactive protein, it is worth in the clinical treatment of coronary heart disease combined hyperlipidemia for more widely used.

View Full Text View/Add Comment Download reader